DNMT1 and glioma: Kaplan–Meier survival analysis further demonstrated that patients with higher DNMT1 expression levels in glioma exhibited lower overall survival rates, disease-specific survival rates, and shorter progression-free periods compared to patients with lower DNMT1 expression levels (Fig. 7B).